Table 1.
Cases of Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Shedding in the Literature
| Time of SARS-CoV-2 RNA Positivity | Age | Sex | CD4 Count, Cells/µL | Viral Load, Copies/mL | ART Regimen at Symptom Onset | Treatment | Author |
|---|---|---|---|---|---|---|---|
| 9 mo | 22 | F | 91 | 5.07 log10 | None | ART | Maponga et al [12] |
| 147 d | 54 | M | 25 | 930 000 | None | Remdesivir, ART | Giubelan et al [13] |
| 92 d | 30 | M | 49 | <20 | Lamivudine, dolutegravir | Prednisone, remdesivir, convalescent plasma, sotrovimab | Montejano et al [14] |
| 66 d | 28 | M | 3 | 563 000 | None | ART | Álvarez et al [15] |
| 98 d | 30 | M | 5 | 109 859 | None | NA | Wenlock et al [16] |
| 85 d | 28 | M | 3 | NA | None | ART | Yousaf et al [17] |
| 216 d | Late 30s | F | 6 | 34 151 | Tenofovir, emtricitabine, and efavirenz | Dexamethasone, new ART regimen | Karim et al [18] |
| 109 d | NA | NA | 3 | 558 000 | None | ART, Pfizer vaccine, bamlanivimab, and etesevimab | Quaranta et al [19] |
| 164 d | 28 | F | NA | NA | Regimen not specified | ART | Maan et al [20] |
| 3 mo | 38 | M | <1 | 980 000 | None | ART, convalescent plasma | Ketels et al [21] |
| 232 d | 38 | M | 663 | <20 | Regimen not specified | None | Cunha et al [22] |
| 107 d | 26 | F | 2 | 198 000 | None | Dexamethasone, ART, convalescent plasma, bamlanivimab, and etesevimab | Spinicci et al [23] |
| 34 d | 49 | F | >600 | <20 | Lamivudine, zidovudine, efavirenz | Interferon, ribavirin, abidol | Menghua et al [24] |
| 2 mo | 40s | NA | 19 | 975 000 | None | ART | Ridell et al [25] |
| 3 mo | 40s | NA | NA | NA | Regimen not specified | New ART regimen | Ridell et al [25] |
| 8.5 mo | 30s | NA | NA | NA | Regimen not specified | New ART regimen, remdesivir | Ridell et al [25] |
Abbreviations: ART, antiretroviral therapy; F, female; M, male; NA, information not available in manuscript; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.